Navigation Links
Neurobiological Technologies Sets Date for First Quarter Financial Results
Date:11/4/2008

EMERYVILLE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its first quarter 2009 financial results, for the quarter ended September 30, 2008, and host a conference call on November 6, 2008.

Hosting the call will be Paul E. Freiman, President and Chief Executive Officer, and Matthew M. Loar, Vice President and Chief Financial Officer. The details for the call are as follows:

Live Call:

-- Date: Thursday, November 6, 2007

-- Time: 10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. PT

-- Dial-in number: 800-309-1245 (U.S.) 719-457-2080 (International)

Webcast of Call:

-- A live webcast can be accessed online by going to:

http://investor.shareholder.com/ntii/events.cfm

Telephonic Replay: (Archived for 90 days)

A playback of the conference call will be available from 1:30 PM November

6 (ET) through midnight November 13 (ET).

Replay number: 888-203-1112 (U.S. and Canada) / 719-457-0820

(international).

Replay access code: 8094663.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
3. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
4. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
5. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
6. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
7. Neurobiological Technologies CEO to Retire on December 31, 2008
8. Neurobiological Technologies Reports Third Quarter Financial Results
9. Neurobiological Technologies Sets Date for Third Quarter Financial Results
10. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
11. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... ... Global Stem Cells Group has announced an inaugural conference and stem cell ... 24-March 6, 2016. The new facility will provide advanced protocols and state-of-the-art techniques in ... CEO Benito Novas will host the event, which will begin with a stem cell ...
(Date:2/12/2016)... 12, 2016  BD (Becton, Dickinson and Company) (NYSE: ... today announced the launch of the BD CLiC™ System ... (AGBT) Meeting. --> ... by providing cost effective NGS library preparation with limited ... fully integrated, next generation sequencing (NGS) library prep instrument, ...
(Date:2/11/2016)... Non-profit Consortium Aims to Generate Genomic Information for ... Discovery --> --> The ... sequence 100,000 individuals. It is intended to initially include populations ... North and East Asian countries. --> ... focus on creating phased reference genomes for all major Asian ...
(Date:2/11/2016)... Germany and GERMANTOWN, Maryland ... ; Frankfurt Prime Standard: QIA) today announced the introduction ... for gene expression profiling, expanding QIAGEN,s portfolio of Sample ... enable researchers to select from over 20,000 human genes ... interactions between genes, cellular phenotypes and disease processes. ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016 This BCC Research ... market by reviewing the recent advances in high ... drive the field forward. Includes forecast through 2019. ... the challenges and opportunities that exist in the ... solution developers, as well as IT and bioinformatics ...
(Date:2/1/2016)... -- Rising sales of consumer electronics coupled ... gesture control market size through ... electronics coupled with new technological advancements to drive global ... through 2020   --> Rising ... to drive global touchfree intuitive gesture control market ...
(Date:1/25/2016)... Pa. , Jan. 25, 2016   Unisys Corporation ... system at John F. Kennedy (JFK) International Airport, New ... Protection (CBP) identify imposters attempting to enter the ... not belong to them. pilot testing of the ... initially at three terminals at JFK during January 2016. --> ...
Breaking Biology News(10 mins):